Advanced	O
Squamous	B:C0007137
Cell	I:C0007137
Carcinoma	I:C0007137
of	O
the	O
Head	O
and	O
Neck	O
:	O
The	O
Current	O
Role	O
of	O
Cetuximab	O
.	O

Advanced	O
Squamous	O
Cell	I:C0007137
Carcinoma	I:C0007137
of	O
the	O
Head	B:C0018670
and	O
Neck	O
:	O
The	O
Current	O
Role	O
of	O
Cetuximab	O
.	O

Advanced	O
Squamous	O
Cell	I:C0007137
Carcinoma	I:C0007137
of	O
the	O
Head	O
and	O
Neck	B:C0027530
:	O
The	O
Current	O
Role	O
of	O
Cetuximab	O
.	O

Advanced	O
Squamous	O
Cell	I:C0007137
Carcinoma	I:C0007137
of	O
the	O
Head	O
and	O
Neck	O
:	O
The	O
Current	O
Role	O
of	O
Cetuximab	B:C0995188
.	O

We	O
review	O
clinical	B:C0008976
trials	I:C0008976
of	O
squamous	O
cell	I:C0007137
carcinoma	I:C0007137
of	O
the	O
head	O
and	O
neck	O
(	O
SCCHN	O
)	I:C0007137
to	O
address	O
the	O
current	O
and	O
potential	O
uses	O
of	O
cetuximab	O
(	O
cetuximab	O
)	O
.	O

We	O
review	O
clinical	O
trials	I:C0008976
of	O
squamous	B:C0007137
cell	I:C0007137
carcinoma	I:C0007137
of	O
the	O
head	O
and	O
neck	O
(	O
SCCHN	O
)	I:C0007137
to	O
address	O
the	O
current	O
and	O
potential	O
uses	O
of	O
cetuximab	O
(	O
cetuximab	O
)	O
.	O

We	O
review	O
clinical	O
trials	I:C0008976
of	O
squamous	O
cell	I:C0007137
carcinoma	I:C0007137
of	O
the	O
head	B:C0018670
and	O
neck	O
(	O
SCCHN	O
)	I:C0007137
to	O
address	O
the	O
current	O
and	O
potential	O
uses	O
of	O
cetuximab	O
(	O
cetuximab	O
)	O
.	O

We	O
review	O
clinical	O
trials	I:C0008976
of	O
squamous	O
cell	I:C0007137
carcinoma	I:C0007137
of	O
the	O
head	O
and	O
neck	B:C0027530
(	O
SCCHN	O
)	I:C0007137
to	O
address	O
the	O
current	O
and	O
potential	O
uses	O
of	O
cetuximab	O
(	O
cetuximab	O
)	O
.	O

We	O
review	O
clinical	O
trials	I:C0008976
of	O
squamous	O
cell	I:C0007137
carcinoma	I:C0007137
of	O
the	O
head	O
and	O
neck	O
(	O
SCCHN	B:C0007137
)	I:C0007137
to	O
address	O
the	O
current	O
and	O
potential	O
uses	O
of	O
cetuximab	O
(	O
cetuximab	O
)	O
.	O

We	O
review	O
clinical	O
trials	I:C0008976
of	O
squamous	O
cell	I:C0007137
carcinoma	I:C0007137
of	O
the	O
head	O
and	O
neck	O
(	O
SCCHN	O
)	I:C0007137
to	O
address	O
the	O
current	O
and	O
potential	O
uses	O
of	O
cetuximab	B:C0995188
(	O
cetuximab	O
)	O
.	O

We	O
review	O
clinical	O
trials	I:C0008976
of	O
squamous	O
cell	I:C0007137
carcinoma	I:C0007137
of	O
the	O
head	O
and	O
neck	O
(	O
SCCHN	O
)	I:C0007137
to	O
address	O
the	O
current	O
and	O
potential	O
uses	O
of	O
cetuximab	O
(	O
cetuximab	B:C0995188
)	O
.	O

PubMed	B:C1138432
was	O
reviewed	O
to	O
identify	O
papers	O
published	I:C0034036
between	O
2010	O
and	O
2016	O
.	O

PubMed	O
was	O
reviewed	O
to	O
identify	O
papers	B:C0034036
published	I:C0034036
between	O
2010	O
and	O
2016	O
.	O

The	O
search	O
terms	O
used	O
were	O
"	O
cetuximab	B:C0995188
"	O
and	O
"	O
head	O
and	I:C0278996
neck	I:C0278996
cancer	I:C0278996
.	O
"	O

The	O
search	O
terms	O
used	O
were	O
"	O
cetuximab	O
"	O
and	O
"	O
head	B:C0278996
and	I:C0278996
neck	I:C0278996
cancer	I:C0278996
.	O
"	O

A	O
total	O
of	O
634	O
articles	B:C0282420
were	O
identified	O
.	O

Phase	B:C1519042
II	I:C1519042
or	I:C1519042
III	I:C1519042
studies	I:C1519042
with	O
cetuximab	O
in	O
patients	O
with	O
advanced	O
squamous	O
cell	I:C0007137
carcinoma	I:C0007137
of	I:C0007137
the	I:C0007137
head	I:C0007137
and	I:C0007137
neck	I:C0007137
without	O
treatment	O
or	O
with	O
recurrent	O
/	O
metastatic	O
tumors	I:C0027627
were	O
selected	O
.	O

Phase	O
II	I:C1519042
or	I:C1519042
III	I:C1519042
studies	I:C1519042
with	O
cetuximab	B:C0995188
in	O
patients	O
with	O
advanced	O
squamous	O
cell	I:C0007137
carcinoma	I:C0007137
of	I:C0007137
the	I:C0007137
head	I:C0007137
and	I:C0007137
neck	I:C0007137
without	O
treatment	O
or	O
with	O
recurrent	O
/	O
metastatic	O
tumors	I:C0027627
were	O
selected	O
.	O

Phase	O
II	I:C1519042
or	I:C1519042
III	I:C1519042
studies	I:C1519042
with	O
cetuximab	O
in	O
patients	O
with	O
advanced	O
squamous	B:C0007137
cell	I:C0007137
carcinoma	I:C0007137
of	I:C0007137
the	I:C0007137
head	I:C0007137
and	I:C0007137
neck	I:C0007137
without	O
treatment	O
or	O
with	O
recurrent	O
/	O
metastatic	O
tumors	I:C0027627
were	O
selected	O
.	O

Phase	O
II	I:C1519042
or	I:C1519042
III	I:C1519042
studies	I:C1519042
with	O
cetuximab	O
in	O
patients	O
with	O
advanced	O
squamous	O
cell	I:C0007137
carcinoma	I:C0007137
of	I:C0007137
the	I:C0007137
head	I:C0007137
and	I:C0007137
neck	I:C0007137
without	O
treatment	B:C0087111
or	O
with	O
recurrent	O
/	O
metastatic	O
tumors	I:C0027627
were	O
selected	O
.	O

Phase	O
II	I:C1519042
or	I:C1519042
III	I:C1519042
studies	I:C1519042
with	O
cetuximab	O
in	O
patients	O
with	O
advanced	O
squamous	O
cell	I:C0007137
carcinoma	I:C0007137
of	I:C0007137
the	I:C0007137
head	I:C0007137
and	I:C0007137
neck	I:C0007137
without	O
treatment	O
or	O
with	O
recurrent	B:C0521158
/	O
metastatic	O
tumors	I:C0027627
were	O
selected	O
.	O

Phase	O
II	I:C1519042
or	I:C1519042
III	I:C1519042
studies	I:C1519042
with	O
cetuximab	O
in	O
patients	O
with	O
advanced	O
squamous	O
cell	I:C0007137
carcinoma	I:C0007137
of	I:C0007137
the	I:C0007137
head	I:C0007137
and	I:C0007137
neck	I:C0007137
without	O
treatment	O
or	O
with	O
recurrent	O
/	O
metastatic	B:C0027627
tumors	I:C0027627
were	O
selected	O
.	O

Forty	O
-	O
six	O
registries	B:C0034975
were	O
obtained	O
.	O

As	O
definitive	O
treatment	B:C0087111
of	O
advanced	O
squamous	O
cells	I:C0007137
carcinomas	I:C0007137
and	O
as	O
palliative	O
treatment	O
of	O
recurrent	O
/	O
metastatic	O
disease	I:C2939420
,	O
cetuximab	O
alone	O
or	O
associated	O
with	O
chemotherapy	O
and	O
/	O
or	O
radiotherapy	O
is	O
an	O
alternative	O
to	O
chemoradiotherapy	O
because	O
of	O
its	O
distinct	O
and	O
favorable	O
toxicity	O
profile	O
.	O

As	O
definitive	O
treatment	O
of	O
advanced	O
squamous	B:C0007137
cells	I:C0007137
carcinomas	I:C0007137
and	O
as	O
palliative	O
treatment	O
of	O
recurrent	O
/	O
metastatic	O
disease	I:C2939420
,	O
cetuximab	O
alone	O
or	O
associated	O
with	O
chemotherapy	O
and	O
/	O
or	O
radiotherapy	O
is	O
an	O
alternative	O
to	O
chemoradiotherapy	O
because	O
of	O
its	O
distinct	O
and	O
favorable	O
toxicity	O
profile	O
.	O

As	O
definitive	O
treatment	O
of	O
advanced	O
squamous	O
cells	I:C0007137
carcinomas	I:C0007137
and	O
as	O
palliative	O
treatment	O
of	O
recurrent	B:C0521158
/	O
metastatic	O
disease	I:C2939420
,	O
cetuximab	O
alone	O
or	O
associated	O
with	O
chemotherapy	O
and	O
/	O
or	O
radiotherapy	O
is	O
an	O
alternative	O
to	O
chemoradiotherapy	O
because	O
of	O
its	O
distinct	O
and	O
favorable	O
toxicity	O
profile	O
.	O

As	O
definitive	O
treatment	O
of	O
advanced	O
squamous	O
cells	I:C0007137
carcinomas	I:C0007137
and	O
as	O
palliative	O
treatment	O
of	O
recurrent	O
/	O
metastatic	B:C2939420
disease	I:C2939420
,	O
cetuximab	O
alone	O
or	O
associated	O
with	O
chemotherapy	O
and	O
/	O
or	O
radiotherapy	O
is	O
an	O
alternative	O
to	O
chemoradiotherapy	O
because	O
of	O
its	O
distinct	O
and	O
favorable	O
toxicity	O
profile	O
.	O

As	O
definitive	O
treatment	O
of	O
advanced	O
squamous	O
cells	I:C0007137
carcinomas	I:C0007137
and	O
as	O
palliative	O
treatment	O
of	O
recurrent	O
/	O
metastatic	O
disease	I:C2939420
,	O
cetuximab	B:C0995188
alone	O
or	O
associated	O
with	O
chemotherapy	O
and	O
/	O
or	O
radiotherapy	O
is	O
an	O
alternative	O
to	O
chemoradiotherapy	O
because	O
of	O
its	O
distinct	O
and	O
favorable	O
toxicity	O
profile	O
.	O

As	O
definitive	O
treatment	O
of	O
advanced	O
squamous	O
cells	I:C0007137
carcinomas	I:C0007137
and	O
as	O
palliative	O
treatment	O
of	O
recurrent	O
/	O
metastatic	O
disease	I:C2939420
,	O
cetuximab	O
alone	O
or	O
associated	O
with	O
chemotherapy	B:C3665472
and	O
/	O
or	O
radiotherapy	O
is	O
an	O
alternative	O
to	O
chemoradiotherapy	O
because	O
of	O
its	O
distinct	O
and	O
favorable	O
toxicity	O
profile	O
.	O

As	O
definitive	O
treatment	O
of	O
advanced	O
squamous	O
cells	I:C0007137
carcinomas	I:C0007137
and	O
as	O
palliative	O
treatment	O
of	O
recurrent	O
/	O
metastatic	O
disease	I:C2939420
,	O
cetuximab	O
alone	O
or	O
associated	O
with	O
chemotherapy	O
and	O
/	O
or	O
radiotherapy	B:C1522449
is	O
an	O
alternative	O
to	O
chemoradiotherapy	O
because	O
of	O
its	O
distinct	O
and	O
favorable	O
toxicity	O
profile	O
.	O

As	O
definitive	O
treatment	O
of	O
advanced	O
squamous	O
cells	I:C0007137
carcinomas	I:C0007137
and	O
as	O
palliative	O
treatment	O
of	O
recurrent	O
/	O
metastatic	O
disease	I:C2939420
,	O
cetuximab	O
alone	O
or	O
associated	O
with	O
chemotherapy	O
and	O
/	O
or	O
radiotherapy	O
is	O
an	O
alternative	O
to	O
chemoradiotherapy	B:C0436307
because	O
of	O
its	O
distinct	O
and	O
favorable	O
toxicity	O
profile	O
.	O

